Clinical Trials Browser

Phase 1 × Active not recruiting × avelumab × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03252938 2026-02-19

INSIGHT

Phase 1 Active not recruiting

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

120 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

17 enrolled

CNS

Neoplasms, Central Nervous System Neoplasms

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT05222932 2025-08-07

AVENTIL

Phase 1 Active not recruiting

15 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Active not recruiting

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03845166 2024-11-19

STELLAR-001

Phase 1 Active not recruiting

325 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

Clinical Trials

COAXIN

INSIGHT

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

AVENTIL

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STELLAR-001